Effect of Prophylactic Ketorolac on CME After Cataract Surgery
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the efficacy of prophylactic administration of the topical
nonsteroidal anti-inflammatory drug (NSAID) ketorolac tromethamine 0.5% (Acular®) on cystoid
macular edema (CME) in patients having undergone cataract surgery. CME is the most frequent
cause of decreased vision after uncomplicated cataract surgery and can result in irreversible
sight reduction. The investigation will involve a comparison arm and a treatment arm with
both sets of patient populations being evaluated for CME with ophthalmologic examinations and
optical coherence tomography (OCT) measurements. The objective is to elucidate the role of
NSAID drops in preventing CME after cataract surgery.